Valproic acid
- Generic Name
- Valproic acid
- Brand Names
- Depakene, Depakote, Epival
- Drug Type
- Small Molecule
- Chemical Formula
- C8H16O2
- CAS Number
- 99-66-1
- Unique Ingredient Identifier
- 614OI1Z5WI
- Background
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...
- Indication
Indicated for:
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
...
- Associated Conditions
- Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode
- Associated Therapies
- -
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
- Conditions
- Interventions
- First Posted Date
- 2007-06-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Korea Otsuka International Asia Arab
- Target Recruit Count
- 127
- Registration Number
- NCT00484471
- Locations
- 🇨🇳
Changhua Chrisitian Hospital, Changhua, Taiwan
🇨🇳Jia-Nan Mental Hospital, Tainan, Taiwan
🇭🇰Castle Peak Hospital, Tuen Mun, Hong Kong
Efficacy of Pregabalin in Migraine Prevention
- Conditions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2008-05-09
- Target Recruit Count
- 70
- Registration Number
- NCT00447369
- Locations
- 🇨🇱
Hospital Militar del General Luis Felipe Brieba Aran, Santiago, Reg. Metropolitana, Chile
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
- Conditions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2018-08-07
- Target Recruit Count
- 62
- Registration Number
- NCT00439673
- Locations
- 🇮🇹
Ospedale Reg. A di Summa, Brindisi, Italy
🇮🇹Ospedale A. Businco, Cagliari, Italy
🇮🇹Università degli studi di Roma La Cattolica, Roma, Italy
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2017-02-23
- Target Recruit Count
- 10
- Registration Number
- NCT00437957
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT00414310
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00385710
- Locations
- 🇫🇷
Service de Neurologie A, Hôpital Gabriel Montpied-BP, Clermont-Ferrand, France
🇫🇷Service de Neurologie, CHU Nantes, Nantes, France
🇫🇷Service de Neurologie et Pathologie du mouvement Hôpital Roger Salingro, CHRU de Lille, Lille, France
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
- Conditions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 42
- Registration Number
- NCT00374075
- Locations
- 🇺🇸
University of Utah/Primary Children's Medical Center, Salt Lake City, Utah, United States
Treatment of Polydrug-Using Opiate Dependents During Withdrawal
- Conditions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2006-08-23
- Lead Sponsor
- Sorlandet Hospital HF
- Target Recruit Count
- 12
- Registration Number
- NCT00367874
- Locations
- 🇳🇴
Sorlandet Hospital HF, Addiction Unit (ARA), Kristiansand, Vest-Agder, Norway
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 42
- Registration Number
- NCT00358319
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.